Molecular Partners AG has concluded its second major deal with a pharmaceutical company in six months, cementing its ongoing three-year-old research program with Johnson & Johnson's business unit, [Janssen Biotech NV], with a strategic research and option agreement involving the treatment of immunological diseases.
"It’s a substantial front-loaded deal, which means that Molecular Partners now has the cash to cover its burn for the next several years," said Molecular Partners' CEO Christian Zahnd. In...